To investigate the prevalence of and independent predictors for digital ischemic complications in patients with systemic sclerosis.
Method:
Patients enrolled in the Siriraj Systemic Sclerosis Cohort registry during 2013–2019 were classified as having or not having digital ischemic complications at the baseline and 1-year timepoints.
Results:
A total of 171 patients with systemic sclerosis were included. The prevalence of digital pulp loss, digital pitting scar, digital ulcer, and digital amputation at baseline and 1 year was 41.5%, 39.8%, 3.5%, 7.6% and 37.4%, 43.9%, 14.1%, 6.4%, respectively. Over half (58.5%) of overall systemic sclerosis had developed new digital ischemic complications during the 1-year follow-up. Those with digital ischemic complications at baseline were at high risk for developing new digital ischemic complications (odds ratio: 15.9). Diffuse cutaneous systemic sclerosis is associated with digital ischemic complications (odds ratio: 6.0), digital pitting scar (odds ratio: 4.9), and digital pulp loss (odds ratio: 6.4). Tendon friction rub is associated with digital pitting scar (odds ratio: 5.0). Salt-and-pepper skin appearance is associated with digital pulp loss (odds ratio: 3.0) and digital ulcer (odds ratio: 6.9). Disease duration > 3 years is associated with digital ulcer (odds ratio: 4.4). Male gender is associated with digital ulcer (odds ratio: 5.4).
Conclusion:
Digital pulp loss, digital pitting scar, digital ulcer, and digital amputation were common manifestations of digital ischemic complications, and diffuse cutaneous systemic sclerosis was the strongest of the six independent predictors.
FurueMMitomaCMitomaH, et al. Pathogenesis of systemic sclerosis—current concept and emerging treatments. Immunol Res2017; 65(4): 790–797.
2.
AsanoYSatoS. Vasculopathy in scleroderma. Semin Immunopathol2015; 37: 489–500.
3.
SilvaIAlmeidaJVasconcelosC. A PRISMA-driven systematic review for predictive risk factors of digital ulcers in systemic sclerosis patients. Autoimmun Rev2015; 14(2): 140–152.
4.
MuangchanC, Canadian Scleroderma Research Group, BaronM, et al. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J Rheumatol2013; 40(9): 1545–1556.
5.
HachullaEClersonPLaunayD, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol2007; 34(12): 2423–2430.
6.
SouzaEMullerCSHorimotoA, et al. Geographic variation as a risk factor for digital ulcers in systemic sclerosis patients: a multicentre registry. Scand J Rheumatol2017; 46(4): 288–295.
7.
WangkaewSSivasomboonCLeungwatthananonW, et al. Prevalence and predictors of hand involvement in Thai patients with systemic sclerosis. Int J Rheum Dis2018; 21(1): 240–248.
8.
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum1980; 23(5): 581–590.
9.
van den HoogenFKhannaDFransenJ, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis2013; 72: 1747–1755.
10.
AletahaDNeogiTSilmanAJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis2010; 69: 1580–1588.
11.
PetriMOrbaiAMAlarcónGS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64(8): 2677–2686.
12.
LundbergIETjärnlundABottaiM, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis2017; 76: 1955–1964.
13.
ShiboskiCHShiboskiSCSerorR, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis2017; 76: 9–16.
14.
SunderkötterCHerrgottIBrücknerC, et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol2009; 160(4): 835–843.
15.
PoormoghimHMoghadamASMoradi-LakehM, et al. Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients. Rheumatol Int2013; 33(8): 1943–1950.
16.
UtsunomiyaAHasegawaMOyamaN, et al. Clinical course of Japanese patients with early systemic sclerosis: a multicenter, prospective, observational study. Mod Rheumatol2021; 31(1): 162–170.
17.
Simeón-AznarCPFonollosa-PláVTolosa-VilellaC, et al. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. Semin Arthritis Rheum2012; 41(6): 789–800.
18.
DentonCPKriegTGuillevinL, et al. Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis2012; 71(5): 718–721.
19.
BrandMHollaenderRRosenbergD, et al. An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database. Clin Exp Rheumatol2015; 33(4 Suppl. 91): S47–S54.
20.
MorrisroeKStevensWSahharJ, et al. Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden. Arthritis Res Ther2019; 21: 299.
21.
WalkerUATyndallACzirjákL, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group database. Ann Rheum Dis2007; 66(6): 754–763.
22.
XuDLiMTHouY, et al. Clinical characteristics of systemic sclerosis patients with digital ulcers in China. Clin Exp Rheumatol2013; 31(2 Suppl. 76): 46–49.
23.
HunzelmannNRiemekastenGBeckerMO, et al. The predict study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodies. Br J Dermatol2016; 174(6): 1384–1387.
24.
TievKPDiotEClersonP, et al. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinérAIR-Sclérodermie). J Rheumatol2009; 36(7): 1470–1476.
25.
KhimdasSHardingSBonnerA, et al. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry. Arthritis Care Res2011; 63(1): 142–149.
26.
SteenVDentonCPPopeJE, et al. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology2009; 48(Suppl. 3): iii19–iii24.
27.
Matucci-CerinicMKriegTGuillevinL, et al. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO registry. Ann Rheum Dis2016; 75(10): 1770–1776.
28.
FoocharoenCPeansukwechUMahakkanukrauhA, et al. Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: a cohort study. Int J Rheum Dis2020; 23(7): 945–957.
29.
WangkaewSTungteerabunditkulSPrasertwittayakijN, et al. Comparison of clinical presentation and incidence of cardiopulmonary complications between male and female Thai patients with early systemic sclerosis: inception cohort study. Clin Rheumatol2020; 39(1): 103–112.
30.
JanardanaRNairAMSurinAK, et al. Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma-do South Asians have a more aggressive disease?Clin Rheumatol2019; 38(11): 3179–3187.
31.
MecoliCAShahAABoinF, et al. Vascular complications in systemic sclerosis: a prospective cohort study. Clin Rheumatol2018; 37(9): 2429–2437.
32.
MedsgerTAJrBombardieriSCzirjakL, et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol2003; 21: S42–S46.
33.
Simeón-AznarCPFonollosa-PláVTolosa-VilellaC, et al. Registry of the Spanish network for systemic sclerosis: survival, prognostic factors, and causes of death. Medicine2015; 94(43): e1728.
34.
KranenburgPvan den HomberghWMKnaapen-HansHK, et al. Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. Rheumatology2016; 55(11):2001–2008.
35.
FoocharoenCSuwannachatPNetwijitpanS, et al. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I. Int J Rheum Dis2016; 19(3): 312–320.
36.
PagalavanLOngSG. Demography, clinical and laboratory features of systemic sclerosis in a Malaysian rheumatology centre. Med J Malaysia2007; 62(2): 117–121.
37.
TehCLKuanYCWongJS. Systemic sclerosis in Sarawak: a profile of patients treated in the Sarawak General Hospital. Rheumatol Int2009; 29(10):1243–1245.
38.
SujauINgCTSthaneshwarP, et al. Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort. Int J Rheum Dis2015; 18(4): 459–465.
39.
AvouacJWalkerUTyndallA, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol2010; 37(7):1488–1501.
40.
HughesMHealCHenesJ, et al. Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology2022; 61: 1141–1147.
41.
LeroyVHenrotPBarnetcheT, et al. Association of skin hyperpigmentation disorders with digital ulcers in systemic sclerosis: analysis of a cohort of 239 patients. J Am Acad Dermatol2019; 80(2): 478–484.
42.
YamaguchiYHearingVJ. Physiological factors that regulate skin pigmentation. Biofactors2009; 35(2): 193–199.
43.
TabataHHaraNOtsukaS, et al. Correlation between diffuse pigmentation and keratinocyte-derived endothelin-1 in systemic sclerosis. Int J Dermatol2000; 39(12): 899–902.
44.
FunauchiMKishimotoKShimazuH, et al. Effects of bosentan on the skin lesions: an observational study from a single center in Japan. Rheumatol Int2009; 29(7): 769–775.
